Back

Monitoring patisiran and inotersen treatment with quantitative SPECT/CT in hereditary transthyretin amyloid cardiomyopathy

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis: prognosis and treatment monitoring Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Rene Rettl

Medical University of Vienna, Vienna (Austria)

6 More presentations in this session

Presentation thumbnail
Prognostic value of different echocardiographic and cardiac magnetic resonance parameters in patients with AL amyloidosis
Doctor A. Hernandez Martos (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Echo-derived hemodynamic categorization for risk stratification in transthyretin cardiac amyloidosis
Doctor A. Cantone (Ferrara, IT)
Abstract Slides Video
Presentation thumbnail
The electrophysiological substrate of biopsy-proven cardiac amyloidosis
Associate Professor M. Casella (Ancona, IT)
Abstract Slides Video
Presentation thumbnail
Interleukin-6 plasma levels predict mortality and heart failure events in cardiac transthyretin amyloidosis
Mr J. Lugitsch (Salzburg, AT)
Abstract Slides Video
Presentation thumbnail
Temporal trends and outcomes of heart failure patients between light-chain cardiac amyloidosis and transthyretin cardiac amyloidosis: insights from the national inpatient sample database
Doctor K. Gandhi (New York, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac amyloidosis: prognosis and treatment monitoring

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources